Crisaborole
- Generic Name
- Crisaborole
- Brand Names
- Eucrisa
- Drug Type
- Small Molecule
- Chemical Formula
- C14H10BNO3
- CAS Number
- 906673-24-3
- Unique Ingredient Identifier
- Q2R47HGR7P
- Background
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older. It reduces the local inflammation in the skin and prevents further exacerbation of the disease with a good safety profile. Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center of the phosphodiesterase 4 enzyme. It is currently under development as topical treatment of psoriasis.
- Indication
Intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.
- Associated Conditions
- Mild Atopic dermatitis, Moderate Atopic dermatitis
Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
- Conditions
- Metastatic Colorectal CancerCetuximabSkin Toxicity
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 33
- Registration Number
- NCT06118047
- Locations
- 🇨🇳
WeiWei Xiao, Guangzhou, Guangdong, China
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
- Conditions
- Vitiligo
- Interventions
- Drug: PF-07038124 0.01% topical ointmentDevice: NBUVB phototherapyDevice: Sham phototherapyDrug: Vehicle
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 32
- Registration Number
- NCT05298033
- Locations
- 🇺🇸
University of Colorado Anschutz - Clinical and Translational Research Centers, Aurora, Colorado, United States
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Vehicle treatmentDevice: Accelerometry device for childrenDevice: Accelerometry device for adult caregivers
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Boston University
- Target Recruit Count
- 72
- Registration Number
- NCT05200403
- Locations
- 🇺🇸
BU CAMed Laboratory for Human Neurobiology, Boston, Massachusetts, United States
Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Applied Biology, Inc.
- Registration Number
- NCT05016284
- Locations
- 🇧🇷
Centro Universitário Nilton Lins, Manaus, Amazonas, Brazil
Characterizing Skin Microbiome Change in Atopic Dermatitis
- Conditions
- Atopic DermatitisAtopic Dermatitis Eczema
- Interventions
- Genetic: Skin Microbiome Swabs
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 20
- Registration Number
- NCT04800185
- Locations
- 🇺🇸
University of California, Irvine - Dermatology Clinical Research, Irvine, California, United States
A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT04498403
- Locations
- 🇯🇵
Mildix Skin Clinic, Adachi-ku, Tokyo, Japan
🇯🇵Sugamo Kobayashi Derma Clinic, Toshima-Ku, Tokyo, Japan
🇯🇵Takagi Dermatological Clinic, Obihiro, Hokkaido, Japan
Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 391
- Registration Number
- NCT04360187
- Locations
- 🇯🇵
Iryouhoujinshadan Yamayurikai Tsujino. Kodomo Clinic, Kobe-City, Hyōgo, Japan
🇯🇵Miyata Dermatology Clinic, Matsudo City, Chiba, Japan
🇯🇵Chitose dermatology and plastic surgery clinic, Chitose Shi, Hokkaido, Japan
Topical Crisaborole in Patients with Alopecia Areata
- Conditions
- Alopecia Areata
- Interventions
- Drug: Placebo Topical Ointment
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Tufts Medical Center
- Registration Number
- NCT04299503
- Locations
- 🇺🇸
Tufts Medical Center, Department of Dermatology, Boston, Massachusetts, United States
Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT04214197
- Locations
- 🇺🇸
MGH Clinical Unit for Research Trials in Skin (CURTIS), Boston, Massachusetts, United States
Skin bioMARkers for Atopic Eczema Therapy Evaluation
- Conditions
- Atopic Eczema/Dermatitis (Non-Specific)
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2021-12-14
- Target Recruit Count
- 37
- Registration Number
- NCT04194814
- Locations
- 🇬🇧
Sheffield Dermatology Research, University of Sheffield Medical School, The Royal Hallamshire Hospital, Sheffield, South Yorkshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.